NSPR vs. ZIMV, SNWV, CATX, NYXH, DRTS, SMTI, BWAY, SKIN, TCMD, and STIM
Should you be buying InspireMD stock or one of its competitors? The main competitors of InspireMD include ZimVie (ZIMV), Sanuwave Health (SNWV), Perspective Therapeutics (CATX), Nyxoah (NYXH), Alpha Tau Medical (DRTS), Sanara MedTech (SMTI), Brainsway (BWAY), Beauty Health (SKIN), Tactile Systems Technology (TCMD), and Neuronetics (STIM). These companies are all part of the "medical equipment" industry.
InspireMD vs. Its Competitors
InspireMD (NYSE:NSPR) and ZimVie (NASDAQ:ZIMV) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.
InspireMD has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500. Comparatively, ZimVie has a beta of 2.07, meaning that its stock price is 107% more volatile than the S&P 500.
InspireMD has higher earnings, but lower revenue than ZimVie. ZimVie is trading at a lower price-to-earnings ratio than InspireMD, indicating that it is currently the more affordable of the two stocks.
44.8% of InspireMD shares are owned by institutional investors. Comparatively, 95.6% of ZimVie shares are owned by institutional investors. 34.1% of InspireMD shares are owned by insiders. Comparatively, 3.0% of ZimVie shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
ZimVie has a net margin of -4.40% compared to InspireMD's net margin of -413.96%. ZimVie's return on equity of 5.53% beat InspireMD's return on equity.
In the previous week, InspireMD had 2 more articles in the media than ZimVie. MarketBeat recorded 2 mentions for InspireMD and 0 mentions for ZimVie. InspireMD's average media sentiment score of 1.73 beat ZimVie's score of 0.00 indicating that InspireMD is being referred to more favorably in the media.
InspireMD presently has a consensus target price of $4.50, indicating a potential upside of 99.56%. ZimVie has a consensus target price of $16.33, indicating a potential upside of 59.51%. Given InspireMD's stronger consensus rating and higher possible upside, equities research analysts plainly believe InspireMD is more favorable than ZimVie.
Summary
InspireMD beats ZimVie on 9 of the 17 factors compared between the two stocks.
Get InspireMD News Delivered to You Automatically
Sign up to receive the latest news and ratings for NSPR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NSPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
InspireMD Competitors List
Related Companies and Tools
This page (NYSE:NSPR) was last updated on 7/6/2025 by MarketBeat.com Staff
Free NSPR Stock Alerts